344 related articles for article (PubMed ID: 34903219)
1. Personalized neoantigen vaccine prevents postoperative recurrence in hepatocellular carcinoma patients with vascular invasion.
Cai Z; Su X; Qiu L; Li Z; Li X; Dong X; Wei F; Zhou Y; Luo L; Chen G; Chen H; Wang Y; Zeng Y; Liu X
Mol Cancer; 2021 Dec; 20(1):164. PubMed ID: 34903219
[TBL] [Abstract][Full Text] [Related]
2. Combination Neoantigen-Based Dendritic Cell Vaccination and Adoptive T-Cell Transfer Induces Antitumor Responses Against Recurrence of Hepatocellular Carcinoma.
Peng S; Chen S; Hu W; Mei J; Zeng X; Su T; Wang W; Chen Z; Xiao H; Zhou Q; Li B; Xie Y; Hu H; He M; Han Y; Tang L; Ma Y; Li X; Zhou X; Dai Z; Liu Z; Tan J; Xu L; Li S; Shen S; Li D; Lai J; Peng B; Peng Z; Kuang M
Cancer Immunol Res; 2022 Jun; 10(6):728-744. PubMed ID: 35476700
[TBL] [Abstract][Full Text] [Related]
3. Preliminary clinical study of personalized neoantigen vaccine therapy for microsatellite stability (MSS)-advanced colorectal cancer.
Yu YJ; Shan N; Li LY; Zhu YS; Lin LM; Mao CC; Hu TT; Xue XY; Su XP; Shen X; Cai ZZ
Cancer Immunol Immunother; 2023 Jul; 72(7):2045-2056. PubMed ID: 36795124
[TBL] [Abstract][Full Text] [Related]
4. Personalized neoantigen vaccine combined with PD-1 blockade increases CD8
Chen H; Li Z; Qiu L; Dong X; Chen G; Shi Y; Cai L; Liu W; Ye H; Zhou Y; Ouyang J; Cai Z; Liu X
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36113894
[TBL] [Abstract][Full Text] [Related]
5. A Neoantigen-Based Peptide Vaccine for Patients With Advanced Pancreatic Cancer Refractory to Standard Treatment.
Chen Z; Zhang S; Han N; Jiang J; Xu Y; Ma D; Lu L; Guo X; Qiu M; Huang Q; Wang H; Mo F; Chen S; Yang L
Front Immunol; 2021; 12():691605. PubMed ID: 34484187
[TBL] [Abstract][Full Text] [Related]
6. Advances in personalized neoantigen vaccines for cancer immunotherapy.
Sun C; Xu S
Biosci Trends; 2020 Nov; 14(5):349-353. PubMed ID: 32908077
[TBL] [Abstract][Full Text] [Related]
7. Caveolin-mediated cytosolic delivery of spike nanoparticle enhances antitumor immunity of neoantigen vaccine for hepatocellular carcinoma.
Lin Z; Jiang C; Wang P; Chen Q; Wang B; Fu X; Liang Y; Zhang D; Zeng Y; Liu X
Theranostics; 2023; 13(12):4166-4181. PubMed ID: 37554274
[No Abstract] [Full Text] [Related]
8. Dose escalation study of a personalized peptide-based neoantigen vaccine (EVX-01) in patients with metastatic melanoma.
Mørk SK; Skadborg SK; Albieri B; Draghi A; Bol K; Kadivar M; Westergaard MCW; Stoltenborg Granhøj J; Borch A; Petersen NV; Thuesen N; Rasmussen IS; Andreasen LV; Dohn RB; Yde CW; Noergaard N; Lorentzen T; Soerensen AB; Kleine-Kohlbrecher D; Jespersen A; Christensen D; Kringelum J; Donia M; Hadrup SR; Marie Svane I
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38782542
[TBL] [Abstract][Full Text] [Related]
9. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
[TBL] [Abstract][Full Text] [Related]
10. Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients.
Yutani S; Ueshima K; Abe K; Ishiguro A; Eguchi J; Matsueda S; Komatsu N; Shichijo S; Yamada A; Itoh K; Sasada T; Kudo M; Noguchi M
J Immunol Res; 2015; 2015():473909. PubMed ID: 26539554
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical study of personalized peptide vaccination combined with radiotherapy for advanced hepatocellular carcinoma.
Shen J; Wang LF; Zou ZY; Kong WW; Yan J; Meng FY; Chen FJ; Du J; Shao J; Xu QP; Ren HZ; Li RT; Wei J; Qian XP; Liu BR
World J Gastroenterol; 2017 Aug; 23(29):5395-5404. PubMed ID: 28839440
[TBL] [Abstract][Full Text] [Related]
12. Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies.
Yutani S; Shirahama T; Muroya D; Matsueda S; Yamaguchi R; Morita M; Shichijo S; Yamada A; Sasada T; Itoh K
Cancer Sci; 2017 Sep; 108(9):1732-1738. PubMed ID: 28622427
[TBL] [Abstract][Full Text] [Related]
13. A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer.
Ott PA; Hu-Lieskovan S; Chmielowski B; Govindan R; Naing A; Bhardwaj N; Margolin K; Awad MM; Hellmann MD; Lin JJ; Friedlander T; Bushway ME; Balogh KN; Sciuto TE; Kohler V; Turnbull SJ; Besada R; Curran RR; Trapp B; Scherer J; Poran A; Harjanto D; Barthelme D; Ting YS; Dong JZ; Ware Y; Huang Y; Huang Z; Wanamaker A; Cleary LD; Moles MA; Manson K; Greshock J; Khondker ZS; Fritsch E; Rooney MS; DeMario M; Gaynor RB; Srinivasan L
Cell; 2020 Oct; 183(2):347-362.e24. PubMed ID: 33064988
[TBL] [Abstract][Full Text] [Related]
14. An immunogenic personal neoantigen vaccine for patients with melanoma.
Ott PA; Hu Z; Keskin DB; Shukla SA; Sun J; Bozym DJ; Zhang W; Luoma A; Giobbie-Hurder A; Peter L; Chen C; Olive O; Carter TA; Li S; Lieb DJ; Eisenhaure T; Gjini E; Stevens J; Lane WJ; Javeri I; Nellaiappan K; Salazar AM; Daley H; Seaman M; Buchbinder EI; Yoon CH; Harden M; Lennon N; Gabriel S; Rodig SJ; Barouch DH; Aster JC; Getz G; Wucherpfennig K; Neuberg D; Ritz J; Lander ES; Fritsch EF; Hacohen N; Wu CJ
Nature; 2017 Jul; 547(7662):217-221. PubMed ID: 28678778
[TBL] [Abstract][Full Text] [Related]
15. Poly-specific neoantigen-targeted cancer vaccines delay patient derived tumor growth.
Aurisicchio L; Salvatori E; Lione L; Bandini S; Pallocca M; Maggio R; Fanciulli M; De Nicola F; Goeman F; Ciliberto G; Conforti A; Luberto L; Palombo F
J Exp Clin Cancer Res; 2019 Feb; 38(1):78. PubMed ID: 30764846
[TBL] [Abstract][Full Text] [Related]
16. Neoantigen Specific T Cells Derived From T Cell-Derived Induced Pluripotent Stem Cells for the Treatment of Hepatocellular Carcinoma: Potential and Challenges.
Lu F; Ma XJ; Jin WL; Luo Y; Li X
Front Immunol; 2021; 12():690565. PubMed ID: 34054880
[TBL] [Abstract][Full Text] [Related]
17. Personalized neoantigen vaccines: A new approach to cancer immunotherapy.
Aldous AR; Dong JZ
Bioorg Med Chem; 2018 Jun; 26(10):2842-2849. PubMed ID: 29111369
[TBL] [Abstract][Full Text] [Related]
18. [Use of autologous tumor vaccine in preventing recurrence of hepatocellular carcinoma].
Peng BG; Liang LJ; He Q; Zhou F; Lai JM; Lü MD; Huang JF
Zhonghua Gan Zang Bing Za Zhi; 2005 Oct; 13(10):772-5. PubMed ID: 16248952
[TBL] [Abstract][Full Text] [Related]
19. Neoantigen cancer vaccines: a new star on the horizon.
Li X; You J; Hong L; Liu W; Guo P; Hao X
Cancer Biol Med; 2023 Dec; 21(4):274-311. PubMed ID: 38164734
[TBL] [Abstract][Full Text] [Related]
20. A Pan-cancer Clinical Study of Personalized Neoantigen Vaccine Monotherapy in Treating Patients with Various Types of Advanced Solid Tumors.
Fang Y; Mo F; Shou J; Wang H; Luo K; Zhang S; Han N; Li H; Ye S; Zhou Z; Chen R; Chen L; Liu L; Wang H; Pan H; Chen S
Clin Cancer Res; 2020 Sep; 26(17):4511-4520. PubMed ID: 32439700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
